Form 4: Dyne Therapeutics CSO Oxana Beskrovnaya Reports Stock Sale to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,153 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• On March 11, 2025, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,153 shares of the company's common stock.
• The sale was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on December 10, 2021, and December 9, 2022.
• The shares were sold at a weighted average price of $11.38, with individual transactions ranging from $11.25 to $11.48.
• Following the transaction, Beskrovnaya directly owns 195,840 shares, which includes 152,839 unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by a company insider to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of the US stock market, and are required by the SEC to provide transparency when company insiders trade their company's stock. This filing indicates that the CSO sold shares to cover tax obligations, which is a common practice.

Key Dates